Favrille Selects Camstar's MES For the Manufacture of Personalized Medicines in the Biotech Industry; Electronic Batch Records Critical as Biopharmaceutical Company Moves Toward Commercialization of its Lead Product Candidate.

CHARLOTTE, N.C. -- Camstar, the leading provider of enterprise manufacturing execution and quality management solutions, announced today that Favrille, a biopharmaceutical company developing patient-specific cancer immunotherapies, has selected Camstar's manufacturing execution system (MES), InSite, to replace the company's current paper-driven batch records to streamline processes.

Favrille is currently in Phase III clinical trials for FavId(R), an active immunotherapy for the treatment of follicular B-cell non-Hodgkin's lymphoma. As the company moves toward commercialization of this product, it is focusing on the implementation of Electronic Batch Records to help scale manufacturing efforts.

"Commercializing a patient-specific immunotherapy product like FavId requires a manufacturing process with an extensive paper batch record," said Tamara A. Seymour, Favrille's Chief Financial Officer. "Camstar's MES solution will replace our paper batch record with an Electronic Batch Record that can streamline the collection and management of manufacturing data. Camstar's advanced technology platform is ideal for handling processes and calculations that are necessary in producing a therapy based on each patient's unique genetic information."

Camstar's InSite will provide Favrille with real-time production information with full traceability and control. The solution will be tightly integrated into an IT environment that consists of ERP, Electronic Document Management (EDM), and various instrumentation and data collection devices. IBM Business Services, a Camstar Systems Integration partner, will lead the implementation effort.

"Camstar's integration with core systems such as ERP and EDM is vital as it ensures that all of our data is current and consistent," said Brad Phillips, Favrille's Senior Director of Information Technology. "Because Camstar partners with IBM Business Services, we have a single, experienced point-of-contact to manage the entire implementation process."

"We are very pleased to be working with Favrille and IBM Business Services," said Rob Rudder, Camstar's Vice President of Sales and Marketing. "Camstar's solutions offer extensive configurability and interoperability, which make them a perfect fit for Biotech companies looking to rapidly commercialize and distribute their products with minimum risk."

About Camstar Systems, Inc.

Camstar is a leading provider of enterprise Manufacturing Execution and Quality Systems. Camstar's InSite and Medical Device Suite applications manage, monitor, and synchronize manufacturing activities across globally distributed plants, and integrates them in real-time with core business processes. Rapid to implement, they provide the manufacturing control needed to help eliminate scrap, rework, paperwork errors and redundant checks. As a result, manufacturers improve yields and product quality, shorten lead times and reach volumes quickly, respond to changing demand, and reduce the cost of compliance. More than 100 leading companies, including Johnson & Johnson, Roche, Tyco, ZOLL, CIBA Vision, Zeiss, Kinetic Concepts, BIOTRONIK, IBM, Kodak, AMD, Philips, Hitachi, SCHOTT, Amkor, ASAT, Renesas, Arcelor and Industeel rely on Camstar as a trusted software partner.

For more information, please visit www.camstar.com.

About Favrille

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase III clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

For more information, please visit www.favrille.com.